Founder’s Vision
ANKTIVA
BCG
Our Science
Careers
Contact
Patients & Caregivers
ANKTIVA®
Clinical Trials
Patients
Therapeutic Areas
Bladder Cancer
Glioblastoma
HIV
Human Papillomavirus
Lymphopenia
Lynch Syndrome
Non-Hodgkin Lymphoma
Non-Small Cell Lung Cancer
Ovarian Cancer
Healthcare Providers
ANKTIVA®
Clinical Trials
Trial Investigators
Expanded Access
Researchers
Platforms & Modalities
Trial Investigators
Cell Licensing
Publications
Our Company
About
Pipeline
Contact
Compliance & Transparency
News and Events
Investors
Select Page
Acceptance Requirements
Adult patients diagnosed with histologically-confirmed glioblastoma that has progressed after initial therapy or therapies
Must have previous first line treatment with at least radiotherapy and temozolomide.
Search for:
Recent Posts
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas
MAHA Action Media Hub
USA–Saudi Biotech Alliance Summit Marks a New Era in Healthspan, Immunotherapy, and Global Scientific Partnership
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy
ASCO GU